As of 2026-09-17, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 15.6x | 14.2x |
| Forward P/E multiples | 17.0x - 20.4x | 18.7x |
| Fair Price | (171.45) - (157.63) | (165.98) |
| Upside | -392.1% - -368.5% | -382.8% |
| Date | EV/EBITDA |